Treatment of metastatic carcinoma using non-viable bacterial BCG formulation
| Project/Area Number |
23592323
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | University of Tsukuba |
|---|
Principal Investigator |
KAWAI Kouji 筑波大学, 医学医療系, 講師 (90272195)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MIYAZAKI Jun 筑波大学, 医学医療系, 准教授 (10550246)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2012: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
Fiscal Year 2011: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Keywords | 泌尿器科 / ビーシージー / 癌免疫 / リポソーム / ミコール酸 / 発光タンパク質 / BCG-CWS / cell wall skeleton / BCG / 膀胱癌 |
|---|
| Research Abstract |
Mycobacteriuma bovis bacillus Calmette-Guerin (BCG) intravesical therapy is a cancer immunotherapy which has been established. However, it is not applicable to metastatic lesion because of side effects caused by live bacteria. We have developed a small-diameter particles of liposome BCG-CWS (cell wall skeleton) with a view to industrialization.
|
Report
(4 results)
Research Products
(4 results)
